Condition: CIN 2/3 · HPV Infection · Pre-Cancerous Dysplasia · Sponsor: Frantz Viral Therapeutics, LLC
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
This description comes directly from the study's public registry record.
Mihaela Plesa, BA, CCRP · 440-255-1155 · FVTinfo@frantzgroup.com
Ahmad Bayat, MD · (301) 956-2523 · ahmadb@amarexcro.com
Always discuss trial participation with your own doctor first.
| Florida Gynecologic Oncology | Fort Myers, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Cleveland Clinic Fairview Hospital | Cleveland, Ohio, United States | Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| Hillcrest Hospital | Mayfield Heights, Ohio, United States | Recruiting |
| The Harris Health System (L.B.J Hospital) | Houston, Texas, United States | Recruiting |
| University of Texas, M.D. Anderson | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04098744